For decades, America’s drug-price debate has centered on a fundamental tension: How do policymakers encourage expensive research and development, while ensuring that companies keep final prices affordable? Studies show that companies will continue to ...

President Trump proposed a plan to lower prescription drug prices, focusing on the "Most Favored Nation" executive order. The plan aims to address the disparity in drug prices between the U.S. and other countries with price controls. Potential solutions ...

President Donald Trump is ramping up the heat on pharmaceutical companies, urging them in letters sent Thursday to cut down drug prices in accordance with an executive order he signed in May. But Trump has limited authority to actually force drug companies ...

The MFN executive order seeks to align US drug prices with those in other developed countries, recently advancing through a voluntary agreement with Pfizer. Legal and procedural challenges exist, with experts debating the MFN's impact on the US bioeconomy ...

The National Pharmaceutical Pricing Authority has revised retail prices of 28 formulations and capped ceiling prices for six drugs under the National List of Essential Medicines

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 28 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-diabetic, anti-hypertensive,

In the first part of this Q&A, Kathy Oubre, MS, discusses how likely it is that the most favored nation executive order will lead to price reductions in prescription drugs. In the first part of this Q&A, Kathy Oubre, MS, chief executive officer of the ...

Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has fixed the